#USA #Washington #Neopharma Technologies #NEOVAULT #Healgen

Neopharma Technologies Partners with Orient Gene to Launch NEOVAULT® for Global Drug Testing

In a groundbreaking move to enhance drug testing integrity, Neopharma Technologies Limited and Zhejiang Orient Gene Biotech Co., Ltd. have announced a global partnership. This collaboration aims to integrate Neopharma's digital platform, NEOVAULT®, into the range of rapid drug tests offered by Orient Gene under the Healgen® brand. With the increasing emphasis on secure and reliable drug testing solutions, this partnership is poised to reshape the landscape of drug screening.

The Need for Advanced Drug Testing Solutions

The demand for innovative drug testing methods has never been more significant, especially with the rise of substance abuse and the need for compliance with U.S. drug policy priorities. This partnership addresses these critical requirements by combining troubleshooting hardware with NEOVAULT®’s cutting-edge digital intelligence.

Key Features of NEOVAULT®

1. Tamper-evident Capture: The NEOVAULT® system offers real-time tamper-evident capture of test results, ensuring data integrity right at the testing point. This is essential in safety-critical environments where the accuracy of drug testing results can have significant implications.

2. Automated Audit Trails: The integration offers automated audit trails, providing a reliable method for tracking test results and ensuring transparency during the testing process.

3. Data Analytics: One of the standout features is its ability to generate instant, de-identified analytics. This helps organizations identify trends related to drug use by different sites and shifts, thus allowing for timely interventions to tackle the issue effectively.

4. Interoperability: NEOVAULT® facilitates secure data transfer by seamlessly integrating with existing Human Resources and clinical systems. This ensures that testing results contribute to compliance, prevention, and reporting efforts in a structured manner.

Alignment with U.S. Drug Policy Priorities

The partnership is particularly timely as it aligns with several priorities set forth by the White House Office of National Drug Control Policy. Specifically, NEOVAULT® contributes to these goals by:

• - Reducing Overdose Fatalities: The software can flag fentanyl-related rapid test results in real time, creating actionable live maps for law enforcement and public health authorities.
• - Innovating Research and Data: By generating reliable, shareable data, NEOVAULT® supports the modernization of the Drugs of Abuse testing industry, tapping into the potential of AI and machine learning to address emerging threats.

Commitment to Security and Compliance

Neopharma's NEOVAULT® is built with the highest security standards in mind, boasting several certifications:

• - ISO 27001: For information security management.
• - SOC 2 Type II: Certifying compliance with Trust Services Criteria.
• - HIPAA Compliance: Ensuring the secure handling of protected health information.
• - GDPR-aligned Controls: Supporting necessary data processing requirements for organizations operating in the EU and UK.

Insights from Executives

The leaders of both companies shared their excitement about this collaboration. Marcus L'Estrange, Executive Chairman of Neopharma, expressed, "We are raising the global standard for digital drug testing. By enabling Healgen®'s extensive DOA portfolio with NEOVAULT®, we transform paper-based results into structured intelligence, aiding employers in making quicker decisions and providing policymakers with real-time insights."

Bryan Fang, President of Orient Gene, added, "Our commitment to improving the accuracy and availability of rapid testing is reinforced through this partnership. We are dedicated to ensuring our customers receive the reliable performance of Healgen® devices alongside the benefits of secure, real-time digital reporting."

Customer Benefits

Customers will be able to enjoy the NEOVAULT®-enabled Healgen® testing devices, which maintain a straightforward workflow while offering features like guided capture and real-time reporting. Additionally, the NEOVAULT® ERM platform will empower Third Party Administrators and Drug Testing businesses to generate digital reports effortlessly, thus streamlining the hiring process with immediate data that typically would take 4-7 days.

With API integrations for common HRIS platforms and role-based access controls, NEOVAULT® not only enhances existing processes but also ushers in a new era of digital drug testing technology.

Conclusion

In conclusion, the partnership between Neopharma Technologies and Orient Gene represents a significant leap forward in the field of drug testing. By efficiently combining advanced technology with a commitment to secure and reliable outcomes, this collaboration is set to redefine how drug tests are administered and analyzed globally. As the industry continues to evolve, innovations like NEOVAULT® will play a crucial role in addressing both current and future challenges in the realm of drug testing.

• ---